{"id":1068567,"date":"2024-08-03T02:35:43","date_gmt":"2024-08-03T06:35:43","guid":{"rendered":"https:\/\/www.immortalitymedicine.tv\/supernus-resubmits-nda-for-spn-830-apomorphine-infusion-device\/"},"modified":"2024-08-18T11:48:56","modified_gmt":"2024-08-18T15:48:56","slug":"supernus-resubmits-nda-for-spn-830-apomorphine-infusion-device","status":"publish","type":"post","link":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/global-news-feed\/supernus-resubmits-nda-for-spn-830-apomorphine-infusion-device.php","title":{"rendered":"Supernus Resubmits NDA for SPN-830 Apomorphine Infusion Device"},"content":{"rendered":"<p><![CDATA[ROCKVILLE, Md., Aug.  01, 2024  (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced it has resubmitted its New Drug Application (NDA) for its apomorphine infusion device (SPN-830) for the continuous treatment of motor fluctuations (OFF episodes) in Parkinson\u2019s disease (PD).]]><\/p>\n<p>Here is the original post:<br \/>\n<a target=\"_blank\" rel=\"nofollow noopener\" href=\"https:\/\/www.globenewswire.com\/news-release\/2024\/08\/01\/2923272\/0\/en\/Supernus-Resubmits-NDA-for-SPN-830-Apomorphine-Infusion-Device.html?f=22&amp;fvtc=5&amp;fvtv=46634288\" title=\"Supernus Resubmits NDA for SPN-830 Apomorphine Infusion Device\">Supernus Resubmits NDA for SPN-830 Apomorphine Infusion Device<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Here is the original post: Supernus Resubmits NDA for SPN-830 Apomorphine Infusion Device <a href=\"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/global-news-feed\/supernus-resubmits-nda-for-spn-830-apomorphine-infusion-device.php\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"limit_modified_date":"","last_modified_date":"","_lmt_disableupdate":"","_lmt_disable":"","footnotes":""},"categories":[1246886],"tags":[],"class_list":["post-1068567","post","type-post","status-publish","format-standard","hentry","category-global-news-feed"],"modified_by":null,"_links":{"self":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/1068567"}],"collection":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/comments?post=1068567"}],"version-history":[{"count":0,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/1068567\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/media?parent=1068567"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/categories?post=1068567"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/tags?post=1068567"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}